| Title: |
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial |
| Authors: |
Qin, S.; Chan, L.S.; Gu, S.; Bai, Y.; Ren, Z.; Lin, X.; Chen, Z.; Jia, W.; Jin, Y.; Guo, Y.; Sultanbaev, A.V.; Pazgan-Simon, M.; Pisetska, M.; Liang, X.; Chen, C.; Nie, Z.; Wang, L.; Cheng, A-L.; Kaseb, A.; Vogel, A. |
| Source: |
Annals of Oncology ; volume 33, page S1401-S1402 ; ISSN 0923-7534 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2022 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/j.annonc.2022.08.032 |
| Availability: |
http://dx.doi.org/10.1016/j.annonc.2022.08.032; https://api.elsevier.com/content/article/PII:S0923753422039102?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0923753422039102?httpAccept=text/plain |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| Accession Number: |
edsbas.AC51BA0 |
| Database: |
BASE |